Ranbaxy unveils two new drugs
Ranbaxy Labs on Monday announced the launch of two Novel Drug Delivery System (NDDS) products in the Urology Segment. Niftran 100mg Capsules developed using the company's R&D capabilities and Eligard 22.5mg & 45mg, in-licensed from QLT Inc, USA, h...
By TNN |
NEW DELHI: Ranbaxy Labs on Monday announced the launch of two Novel Drug Delivery System (NDDS) products in the Urology Segment. Niftran 100mg Capsules developed using the company's R&D capabilities and Eligard 22.5mg & 45mg, in-licensed from QLT Inc, USA, have been launched in the Indian market.
The launch of Niftran and Eligard reinforces our commitment in the NDDS segment and Th "The launch of Niftran and Eligard reinforces our commitment in the NDDS segment and further consolidates our leadership position in this area. Both these drugs augment our Urology franchise and present our customers with Innovative drugs which offer superior options and convenience," Ranbaxy Senior VP and Regional Director (Asia), Sanjeev Dani said in a press release.
Niftran, a Novel Drug Delivery System (NDDS) based product, offers better patient compliance due to twice-a-day dosage regimen compared to the conventional four times-a-day dosage regimen with the currently available Nitrofurantoin in the market. Niftran is indicated for the use in Urinary Tract Infections.
Eligard is indicated for the palliative treatment of advanced prostate cancer. Eligard is also an NDDS based hormonal therapy available in dosage forms of 22.5mg (3 months depot) & 45mg (6 months depot).
Ranbaxy has a market share of 8% within the NDDS segment. NDDS portfolio contribution to total Ranbaxy sales stands at 9% in moving quarter November, 2006, according to ORG-IMS; MAT November 2006.
The launch of Niftran and Eligard reinforces our commitment in the NDDS segment and Th "The launch of Niftran and Eligard reinforces our commitment in the NDDS segment and further consolidates our leadership position in this area. Both these drugs augment our Urology franchise and present our customers with Innovative drugs which offer superior options and convenience," Ranbaxy Senior VP and Regional Director (Asia), Sanjeev Dani said in a press release.
Niftran, a Novel Drug Delivery System (NDDS) based product, offers better patient compliance due to twice-a-day dosage regimen compared to the conventional four times-a-day dosage regimen with the currently available Nitrofurantoin in the market. Niftran is indicated for the use in Urinary Tract Infections.
Eligard is indicated for the palliative treatment of advanced prostate cancer. Eligard is also an NDDS based hormonal therapy available in dosage forms of 22.5mg (3 months depot) & 45mg (6 months depot).
Ranbaxy has a market share of 8% within the NDDS segment. NDDS portfolio contribution to total Ranbaxy sales stands at 9% in moving quarter November, 2006, according to ORG-IMS; MAT November 2006.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
